166 filings
Page 3 of 9
8-K
9a096g uut2
10 Nov 22
T2 Biosystems Announces Third Quarter 2022 Financial Results
5:01pm
8-K
xwx52wpmu
7 Nov 22
Departure of Directors or Certain Officers
9:00am
8-K
83rlk23550kf
14 Oct 22
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
9:00am
8-K
hc2bjxb zi56lhdx
13 Oct 22
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
9:00am
8-K
q3rkb27fn
12 Oct 22
Material Modifications to Rights of Security Holders
4:01pm
8-K
lloi4mh4c3w2wiq5b1
12 Oct 22
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
8:47am
8-K
5mhs6 losv6d5n
30 Sep 22
Entry into a Material Definitive Agreement
4:06pm
8-K
he2jg
30 Sep 22
Entry into a Material Definitive Agreement
4:00pm
8-K
b4f2n5io606064xz33jc
30 Aug 22
Other Events
9:00am
8-K
xye3np
17 Aug 22
T2 Biosystems Announces Second Quarter 2022 Financial Results
4:00pm
8-K
5t48bxl24wauww
9 Aug 22
T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Philip Trip Taylor, Gilmartin Group
8:31am
8-K
wj4eh0 d553x
25 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10:00am
8-K
ud1bzu
11 Jul 22
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
8:30am
8-K
2m8e3y6z99eohe3gkf
6 Jul 22
T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results
8:43am
8-K
uv6on7v2g905q 26hz0
10 Jun 22
Other Events
8:50am
8-K
7hj4qot0
24 May 22
Other Events
5:01pm
8-K
4cou0
11 May 22
T2 Biosystems Announces First Quarter 2022 Financial Results
4:25pm
8-K
l8bgmu
27 Apr 22
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel
8:30am
8-K
0blmbpogqtxt92
12 Apr 22
Regulation FD Disclosure
4:01pm
8-K/A
ynraw95k
1 Apr 22
Entry into a Material Definitive Agreement
4:01pm